Health Condition 1: P293- Persistent fetal circulation
Conditions
Interventions
Intervention1: Oral sildenafil in management of pphn.: â?¢Babies randomised into oral sildenafil group will be given 2 mg/kg per dose every 6th hourly. Oral tablet of Sildenafil of strength 20 mg will
Sponsors
Department of Neonatology
Eligibility
Inclusion criteria
Inclusion criteria: Neonates with 34 weeks of completed gestational age who are echocardiographically diagnosed to have Persistent pulmonary hypertension of the newborn defined as 1.PASP of more than 35 mm of Hg calculation by TR peak jet velocity and Fio2 requirement > 21%
Exclusion criteria
Exclusion criteria: 1. Congenital heart disease (Except patent ductus arteriosus, atrial septal defect ( 2. Congenital diaphragmatic hernia 3. Lethal congenital anomaly 4. Babies with severe PPHN with Oxygenation index (OI) > 15 and directly started on inhaled nitric oxide (iNO) on diagnosis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the time taken for pulmonary artery systolic pressure (PASP) to decrease below 30 mm Hg among neonates diagnosed with PPHN receiving oral sildenafil as compared to those receiving oral bosentan.Timepoint: 1 month | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare oral sildenafil and bosentan in neonates with PPHN in terms of â?¢Duration of ventilation â?? both invasive, non-invasive and nasal oxygen â?¢Duration of hospital stay â?¢Time taken to reach room air â?¢Failure rates â?¢Mortality â?¢To compare the time to achieve full feeds in both groups Timepoint: 1 month | — |
Countries
India
Contacts
Public ContactShreya S Nandikol
Bharati Vidyapeeth University
Outcome results
None listed